<div id="readability-page-1"><div><p>The Central Drugs Standard Control Organisation (CDSCO) has asked states and union territories (UTs) to actively monitor print, electronic, digital, social media, and outdoor platforms for surrogate promotional activities related to weight-loss drugs such as semaglutide.</p></div><div><div><div id="article-index-0">  <p>  This comes after India’s apex drug regulatory body had asked all drugmakers having marketing authorisation to sell glucagon-like peptide (GLP-1) drugs for obesity management not to partake in any promotional activities for the prescription-only therapy.</p> </div><div id="article-index-1">  <p>  In a circular dated March 27, the CDSCO stated that appropriate action could be taken under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, against manufacturers, importers, marketers, or any other entities found in violation of the rules.</p> </div><div id="article-index-2">  <p>  “Over the past several weeks, the CDSCO, in coordination with state licensing authorities, has undertaken a nationwide enforcement drive to curb illegal distribution channels, non-compliant dispensing practices, and misuse of GLP-1 drug use,” said Drug Controller General Rajeev Raghuvanshi.</p> </div><div id="article-index-3">  <p>  He added that several audits and inspections have already been carried out, including at online pharmacy warehouses, drug wholesalers, retail outlets, and slimming clinics, with notices being served to entities found in violation of conditions of permission and on-label warnings.</p> </div><div id="article-index-4">  <p>  Recently, the Haryana Food and Drug Administration (FDA) had seized counterfeit versions of its diabetes drug Mounjaro in Gurugram.</p> </div><div id="article-index-5">  <p>  Marketed by US-based drugmaker Eli Lilly, the counterfeit products were neither manufactured by Lilly nor did they originate from the company’s authorised and verified supply chain.</p> </div><div id="article-index-6">  <p>  With Novo Nordisk’s blockbuster GLP-1 agonist drug semaglutide, better known by its brand name Ozempic, going off patent on March 20, Indian markets have been flooded with more than 25 cheaper generic versions.</p> </div><div id="article-index-7">  <p>  Consequently, several pharmaceutical companies had stepped up multimedia awareness campaigns, not directly promoting their drugs, but building awareness around obesity being a disease and encouraging users to consult doctors, as the race for India’s GLP-1 drug market intensifies.</p> </div><div id="article-index-8">  <p>  Over the past year, new launches in the injectable GLP-1 agonist segment — such as Mounjaro, Wegovy, and Ozempic — have already driven a 218 per cent rise in sales in this category on a moving annual turnover (MAT) basis to Rs 1,736 crore in April 2026, compared with Rs 545 crore in April 2025.</p> </div><div id="article-index-9">  <p>  Of these, Mounjaro and Ozempic are currently approved in India only for Type-2 diabetes, and prescriptions are restricted to diabetic patients.</p> </div><div id="article-index-10">  <p>  However, with awareness among the broader population limited, companies are turning to multimedia campaigns focused on obesity awareness since Indian regulations prohibit direct-to-consumer drug advertising.</p> </div><div id="article-index-11">  <p>  India’s large disease burden has also made it an attractive market for weight-loss therapies. According to World Health Organization (WHO) estimates for 2023-24, the country has around 101 million people living with diabetes, and another 136 million with pre-diabetes.</p> </div><div id="article-index-12">  <p>Studies suggest India also has 254 million people with generalised obesity, and 351 million with abdominal obesity.</p> </div></div></div></div>

诺和诺德公司

<p>印度中央药品标准控制组织（CDSCO）已指示各州和联邦直辖区监控 GLP-1 减肥药物（如 semaglutide）的推广活动，此举是在对处方药物的推广活动实施禁令之后。该组织通过审计和检查来强制执行合规，解决非法分销和滥用问题。随着 semaglutide 专利的到期，已有超过 25 种仿制药版本问世，促使公司推出以肥胖意识为重点的多媒体宣传活动，因为直接广告是被禁止的</p>

印度中央药品标准控制组织（CDSCO）要求各州和联邦属地监控 GLP-1 药物的替代性促销活动